We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effect of Peptide Receptor Radionuclide Therapy in Combination with Temozolomide against Tumor Angiogenesis in a Glioblastoma Model.
- Authors
Lee, Sang Hee; Choi, Ji Young; Jung, Jae Ho; Song, In Ho; Park, Hyun Soo; Denora, Nunzio; Leonetti, Francesco; Kim, Sang Eun; Lee, Byung Chul
- Abstract
Simple Summary: Glioblastoma multiforme (GBM) is an aggressive brain tumor characterized by intense angiogenesis. Thus, tumor angiogenesis-related receptors, such as the cell adhesion molecule integrin αvβ3, are potential biomarkers for cancer diagnosis and therapy. In this study, we aimed to investigate the therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) with 188Re-IDA-D-[c(RGDfK)]2 (11.1 MBq). Our results revealed that PRRT combined with temozolomide markedly reduced the tumor volume compared with monotherapy. In summary, 188Re-IDA-D-[c(RGDfK)]2 might be an effective radiotherapeutic agent for the treatment of GBM. Cell adhesion receptor integrin αvβ3 is a promising biomarker for developing tumor-angiogenesis targeted theranostics. In this study, we aimed to examine the therapeutic potential of peptide receptor radionuclide therapy (PRRT) with 188Re-IDA-D-[c(RGDfK)]2 (11.1 MBq). The results showed that the tumor volume was significantly decreased by 81% compared with the vehicle-treated group in U87-MG xenografts. The quantitative in vivo anti-angiogenic responses of PRRT were obtained using 99mTc-IDA-D-[c(RGDfK)]2 SPECT and corresponded to the measured tumor volume. PRRT combined with temozolomide (TMZ) resulted in a 93% reduction in tumor volume, which was markedly greater than that of each agent used individually. In addition, histopathological characterization showed that PRRT combined with TMZ was superior to PRRT or TMZ alone, even when TMZ was used at half dose. Overall, our results indicated that integrin-targeted PRRT and TMZ combined therapy might be a new medical tool for the effective treatment of glioblastoma.
- Subjects
RADIOISOTOPE therapy; XENOGRAFTS; CELL culture; IMMUNOHISTOCHEMISTRY; MICROSCOPY; GLIOMAS; CELL receptors; ANTINEOPLASTIC agents; QUANTITATIVE research; TREATMENT effectiveness; TEMOZOLOMIDE; PATHOLOGIC neovascularization; DESCRIPTIVE statistics; HISTOLOGY; VASCULAR endothelial growth factors
- Publication
Cancers, 2021, Vol 13, Issue 19, p5029
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers13195029